All translations
Jump to navigation
Jump to search
Enter a message name below to show all available translations.
Found 2 translations.
| Name | Current message text |
|---|---|
| h English (en) | As of 2022, no medication has been discovered that would equal the effectiveness of [[bariatric surgery]] for long-term weight loss and improved health outcomes. {| class="wikitable" |+ !Medication Name !Trade name(s) !Mechanism of action !Current FDA Status !placebo-adjusted percent bodyweight lost (highest dose studied) |- |[[Semaglutide]] |Wegovy |[[GLP-1 receptor agonist]] |Approved for weight management (chronic) |12% |- |[[Phentermine/topiramate]] |Qsymia |Phentermine is a [[substituted amphetamine]] and topiramate has an unknown mechanism of action |Approved for weight management (short-term) by the FDA but not the European Medicines Agency |10% or {{convert|8.25| kg}} |- |[[Naltrexone/bupropion]] |Contrave | |Approved for weight management (chronic) in the US and EU |5 percent |- |[[Liraglutide]] |Saxenda |[[GLP-1 receptor agonist]] |Approved for weight management (chronic) |4 percent |- |[[Gelesis100]] |Plenity |Oral hydrogel |FDA approved for weight management (chronic) but the American Gastroenterology Association recommends that its use be limited to [[clinical trials]] due to lack of evidence. |2% |- |[[Orlistat]] |Xenical |Absorption inhibitor |Approved for weight management (chronic) |{{convert|3|kg}}; percentage not provided |- |[[Phentermine]] | |[[Substituted amphetamine]] |Approved for weight management (short-term) |{{convert|5|kg}} |- |[[Methamphetamine]] |Desoxyn |[[Substituted amphetamine]] |Approved for weight management (short-term) | |- |[[Tirzepatide]] |Zepbound |Dual [[GLP-1 receptor agonist]] and [[Glucose-dependent insulinotropic polypeptide|GIP agonist]] |FDA approved for weight management (chronic); EMA approval for weight loss is pending |{{convert|10.91|kg}} |} |
| h Japanese (ja) | 2022年現在、長期的な体重減少や健康状態の改善において、[[bariatric surgery/ja|肥満手術]]の効果に匹敵する医薬品は発見されていない。 {| class="wikitable" |+ !医薬品名 !商品名 !作用機序 !現在のFDAステータス !プラセボ調整による体重減少率（最高用量試験） |- |[[Semaglutide/ja]] |ウゴービ |[[GLP-1 receptor agonist/ja]] |体重管理（慢性）の承認 |12% |- |[[Phentermine/topiramate/ja]] |キシミア |フェンテルミンは[[substituted amphetamine/ja|置換アンフェタミン]]であり、トピラマートは作用機序が不明である。 |FDAは体重管理（短期）を承認したが、欧州医薬品庁は承認していない。 |10% あるいは {{convert|8.25| kg}} |- |[[Naltrexone/bupropion/ja]] |コントレイブ | |米国およびEUで体重管理（慢性）の承認を取得 |5% |- |[[Liraglutide/ja]] |サクセンダ |[[GLP-1 receptor agonist/ja]] |体重管理（慢性）の承認 |4% |- |[[Gelesis100/ja]] |プレニティ |経口ヒドロゲル |FDAは体重管理（慢性）のために承認したが、米国消化器病学会はエビデンス不足のため、その使用を[[clinical trials/ja|臨床試験]]に限定するよう勧告している。 |2% |- |[[Orlistat/ja]] |ゼニカル |吸収阻害剤 |体重管理（慢性）の承認 |{{convert|3|kg}}; %は提供されていない |- |[[Phentermine/ja]] | |[[Substituted amphetamine/ja]] |体重管理に承認（短期） |{{convert|5|kg}} |- |[[Methamphetamine/ja]] |デソキシン |[[Substituted amphetamine/ja]] |体重管理に承認（短期） | |- |[[Tirzepatide/ja]] |ゼップバウンド |デュアル[[GLP-1 receptor agonist/ja]]と[[Glucose-dependent insulinotropic polypeptide/ja|GIP作動薬]] |FDAは体重管理（慢性）の適応で承認、EMAは体重減少の適応で承認申請中である |{{convert|10.91|kg}} |} |